XML 49 R31.htm IDEA: XBRL DOCUMENT v2.4.1.9
Collaboration and License Agreements (Tables)
 12 Months Ended
Dec. 31, 2014
Revenue Recognition [Abstract]  
Summary of Revenue from Collaboration and License Agreements

We have recognized revenue from our collaboration and license agreements as follows (in thousands):

 

 

 

Year Ended December 31,

 

 

 

2014

 

 

2013

 

 

2012

 

Novartis:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of upfront license fee

 

$

–

 

 

$

–

 

 

$

53,846

 

Reimbursement of research and development expense

 

 

–

 

 

 

–

 

 

 

16,238

 

Novartis total

 

 

–

 

 

 

–

 

 

 

70,084

 

BMS and Pfizer:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of research and development services

 

 

1,497

 

 

 

4,042

 

 

 

1,958

 

BMS and Pfizer total

 

 

1,497

 

 

 

4,042

 

 

 

1,958

 

Bayer and Janssen:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of research and development services

 

 

3,598

 

 

 

3,876

 

 

 

–

 

Bayer and Janssen total

 

 

3,598

 

 

 

3,876

 

 

 

–

 

Lee’s:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of research and development services

 

 

243

 

 

 

194

 

 

 

–

 

Lee’s total

 

 

243

 

 

 

194

 

 

 

–

 

Daiichi Sankyo:

 

 

 

 

 

 

 

 

 

 

 

 

Recognition of research and development services

 

 

4,287

 

 

 

2,419

 

 

 

–

 

Daiichi Sankyo total

 

 

4,287

 

 

 

2,419

 

 

 

–

 

Total collaboration and license revenue

 

$

9,625

 

 

$

10,531

 

 

$

72,042